Curriculum Vitae

Jeremy Frieling

Research Scientist
Department of Tumor Microenvironment & Metastasis, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

Educational Background & Professional Experience

2021.5–Present	Research Scientist I, Department of Microenvironment & Metastasis, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
2017.9–2021.5	Postdoctoral Research Fellow, Department of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
2017.5–2017.8	Mass Media Science & Engineering Communications Fellow, American Association for the Advancement of Science, Washington D.C., USA
2010.8–2017.4	Doctoral Candidate, Department of Cancer Biology, University of South Florida, Tampa, FL, USA

Research Interests

Skeletal malignancy, tumor–bone microenvironment interactions, immune–based therapies for bone metastatic tumors

Publications

1. JS Frieling and CC Lynch. Tales of cancer–induced bone disease from the senescent osteocyte crypt. Cancer Research. 2024.
2. KJ Nyman, JS Frieling, and CC Lynch. Emerging roles for stromal cells in bone metastasis. Journal of Bone Oncology. 2024.
3. RT Bishop, T Li, PR Sudalagunta, M Nasr, KJ Nyman, RR Alugubelli, M Meads, JS Frieling, N Nerlakanti, M Tauro, B Fang, S Grant, J Koomen, AS Silva, KH Shain, CC Lynch. Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed / refractory multiple myeloma. Haematologica. 2024.
4. RT Bishop, AK Miller, M Froid, N Nerlakanti, T Li, JS Frieling, M Nasr, KJ Nyman, PR Sudalagunta, RR Canevarolo, AS Silva, KH Shain, CC Lynch, and D Basanta. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogenous drug resistant disease. Nature Communications. 2024.
5. JS Frieling and L Tordesillas, XE Bustos, MC Ramello, RT Bishop, JE Cianne, SA Snedal, T, CH Lo, J de la Iglesia, E Roselli, I Benzaïd, X Wang, Y Kim, CC Lynch and D Abate–Daga. γδ–Enriched CAR–T cell therapy for bone metastatic castrate–resistant prostate cancer. Science Advances. 2023.